Primary resistance may be due to a relative lack of tumour PD-L1 expression, with data for various cancers showing that patients with tumour biopsies with PD-L1 positivity by immunohistochemistry have higher response rates than those with PD-L1 negative disease [294]. The gene discussed is CD274; the disease is neoplasm.